Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc99m-Maraciclatide Scintigraphy in Diabetic HFpEF
NCT01440517Phase 2Terminated
- Sponsor
- GE HealthCare
- Start
- Aug 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 99mTc maraciclatide in heart failure with preserved ejection fraction (HFpEF), type 2 diabetes mellitus (T2DM), sponsored by GE HealthCare. Started Aug 2011; status: terminated.
02
Drugs
99mTc maraciclatide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01440517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440517.